Phage Based Diagnostics

01359 231856

Twitter Youtube Linkedin Envelope
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Menu
  • Home
  • About
    • About PBD Biotech
    • Industry Awards
    • Management Team
    • International
  • Actiphage
    • About Actiphage
    • Benefits of Actiphage
    • Rapid detection of mycobacterial disease
  • Bovine
    • Bovine TB
    • Johne’s Disease
  • Latest
    • Articles
    • Events
  • Case Studies
  • Research
  • Contact
    • Product Order Form
    • Contacting us
Search
Generic filters

Human TB study into new blood test achieves funding following successful proof of concept

Worldwide a quarter of a million children die of tuberculosis (TB) each year, early diagnosis would help to save their lives but most are unable to produce the sample of mucus that is needed for the current test.
  • December 27, 2019
  • Human health

Actiphage®, developed by PBD Biotech, is a blood test for TB that was originally developed for cattle and other animals, which offers potential as an alternative diagnostic.

Following its successful proof-of-concept trial, the University Hospitals of Leicester have gained further funding for a pilot programme as the next step towards full validation of Actiphage for use in humans.

The collaborative study, between the University Hospitals of Leicester, University of Nottingham and PBD Biotech, has gained Medical Research Council funding. This funding has allowed a larger cohort of patients to be tested and researchers are co collecting data from almost 100 patients with both active and latent TB infection. The aim is to provide additional evidence for the use of Actiphage as a rapid, cost-effective tool to detect Mycobacterium tuberculosis, the pathogen that causes TB in humans.

TB is the world’s most deadly infectious disease and latest figures show an estimated 10 million people worldwide fall ill with the serious bacterial infection (WHO, 2018).

Currently, the only rapid diagnostics for TB rely on testing sputum – phlegm brought up from the deep in the lungs – however 40% of adults with TB and the majority of children struggle to bring up phlegm. Additionally, it is difficult to culture the slow growing bacteria on plates, yet this is the current gold standard diagnostic.

Actiphage can detect mycobacteria in a single blood sample. It uses a specific bacteriophage virus that multiplies rapidly in live mycobacterial cells; a natural process, which causes the cells to burst open releasing their DNA that can then be identified using PCR tests. So, Actiphage can be used to detect very low levels of infection, often before symptoms have developed and the disease becomes contagious.

The earlier proof-of-concept work using Actiphage, published in medical journal Clinical Infectious Diseases (June 2019), showed that the test could detect the presence of Mycobacterium tuberculosis in blood – not only in patients with active disease but also in the very early stages of infection.

The test was able to identify live mycobacteria in the blood of three patients with latent TB, and two of these were the only ones from the latent TB group who went on to developed active TB more than six months later; indicating that Actiphage could have a predictive role in identifying people with the infection at risk of developing the disease.

Mark Hammond, CEO of PBD Biotech, comments: “Actiphage is a unique blood test for TB and is currently being used to improve disease management within farm animals and wildlife, to provide early detection of disease. It is known that TB is zoonotic and can be transmitted from animals to humans, or through unpasteurised dairy products, so having a rapid tool that can be deployed in a One Health approach to managing the disease would be highly beneficial.”

Preliminary results and early evidence from the latest Actiphage trial across Leicester’s Hospitals will be available mid-2020.

Share:

Related posts

Loading...
Actiphage use as a DIVA test

Actiphage optimised to detect MAP in humans and to support use as ‘DIVA’

June 1, 2022
This is the first time Actiphage has been used to detect MAP in a human blood sample and also to identify a live infection in a vaccinated goat.
Actiphage use as a DIVA test

Actiphage optimised to detect MAP in humans and to support use as ‘DIVA’

June 1, 2022
This is the first time Actiphage has been used to detect MAP in a human blood sample and also to...
cow

Why breakthrough human trials of Actiphage are good news for farmers

May 12, 2022
The findings are a real breakthrough for animal diagnosis as it provides clinical evidence that detection of low levels of mycobacteria in the blood is an indication that the animal is infected and has the potential to develop disease.
cow

Why breakthrough human trials of Actiphage are good news for farmers

May 12, 2022
The findings are a real breakthrough for animal diagnosis as it provides clinical evidence that detection of low levels of...
ECCMID

Actiphage® TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live bacteria can be detected in the blood of people with incipient TB infection.
ECCMID

Actiphage® TB diagnostic finds live mycobacterium tuberculosis in the blood of people with incipient TB

April 23, 2022
A clinical trial of Actiphage, a promising new diagnostic for tuberculosis infection, has shown for the first time that live...
rapid TB test World TB Day - Zambart image

Could Actiphage provide rapid TB test in sub-Saharan Africa?

March 23, 2022
Sub-Saharan Africa is devastated by TB disease. Zambia, has a high TB/HIV burden – 59,000 people developed TB in 2020 and 15,000 died. There is a critical need for a non-sputum based rapid test for diagnosing TB disease.
rapid TB test World TB Day - Zambart image

Could Actiphage provide rapid TB test in sub-Saharan Africa?

March 23, 2022
Sub-Saharan Africa is devastated by TB disease. Zambia, has a high TB/HIV burden – 59,000 people developed TB in 2020...
1 2 Next »

developers of phage-based diagnostics

Contact Us

PBD Biotech Ltd
Link House, Elm Farm Park,
Great Green, Thurston,
Suffolk IP31 3SH,
United Kingdom

Registered Company Address
Ingenuity Centre,
University of Nottingham,
Innovation Park, Triumph Rd,
Nottingham NG7 2TU,
United Kingdom

T: 01359 231856
info@pbdbio.com

Privacy and cookies policy

© 2022 PBD Biotech Ltd

design: out of house

  • Follow Us!
PBD Biotech

If you are going @CheshireShow there is an opportunity to talk to @ZaraBewizibet senior scientific adviser to Defra TB Policy. She is on the Cheshire Badger Vaccination Project @CBVP2021 stand. Good to see some joined up thinking #BadgerTrust #EndTB

Read More
PBD Biotech

@PeterMullowney Thank you @PeterMullowney for a very productive conference with many inspiring presentations. So good to see everyone @paratb2022

Read More
PBD Biotech

@1GarethWynJones @downtoearthuk_ @clovermad Mum always knows best 😉 Well done @clovermad for hosting.

Read More